Clinical Trial Update: Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated With Aflibercept (FORESIGHT) [Phase 4]

View source ↗

Summary

This Phase 4 FORESIGHT trial update reports changes in inflammatory biomarkers, including soluble CD14 and hyperreflective foci, in patients with diabetic macul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Hyewon Chung | Conditions: Diabetic Macular Edema | Phase 4 | Status: COMPLETED